Bristol Myers Squibb, announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) to add positive data from...
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for repotrectinib, a next-generation tyrosine...
Tubulis and Bristol Myers Squibb announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates (ADCs).
Through the license agreement, Bristol Myers...
Lyvgen Biopharma, a leading innovative global biotech company dedicated to discovering, developing and commercializing first-in-class and best-in-class biotherapeutics for cancer, announced an open label,...
Amphista Therapeutics, a global leader in the discovery and development of next generation targeted protein degradation (TPD) therapeutics, announced a strategic collaboration and license...
